Johnson & Johnson Highlights New Data That Showcase the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living With Generalized Myasthenia Gravis (gMG)
April 09, 2025
April 09, 2025
NEW BRUNSWICK, New Jersey, April 9 -- Johnson and Johnson issued the following news release:
* * *
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 . . .
* * *
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 . . .